The Beljanski Cancer Talk Show

EP 36 - What Your Urine & Tumor Tissue Reveal About Your Cancer with Dr. John A. Catanzaro

• The Beljanski Foundation • Season 1 • Episode 36

Share episode

In this powerful episode of The Beljanski Cancer Talk Show, we welcome Dr. John Catanzaro, founder and CEO of Neo7 Bioscience, for a groundbreaking conversation on precision molecular medicine and personalized peptide therapies.

Discover how N-of-1 treatment strategies—tailored to your unique biology—are offering new hope to patients, especially those with drug-resistant cancers, chronic illness, and complex conditions.

🧠 What You’ll Learn:

  • How personalized peptide therapy works using your genetic and protein profile
  • The link between environmental toxins, emotional trauma, and cancer
  • The role of molecular diagnostics in uncovering root causes
  • A step-by-step look at the Neo7 Bioscience process—from testing to treatment
  • Real case studies where personalized approaches made a difference

Dr. Catanzaro shares how this innovative approach complements conventional cancer care, helping patients explore broader, biology-based options rooted in science—not speculation.
► https://www.beljanski.org/beljanski-cancer-talk-show/episode-36-what-your-urine-tumor-tissue-reveal-about-your-cancer-featuring-dr-john-a-catanzaro-n-m-d-ph-d-2/

🎧 Listen if you’re seeking:
• Functional & integrative medicine alternatives
• Advanced tools for cancer care
• Personalized options after failed standard treatment
• Hope and direction in complex medical situations

🔗 Resources Mentioned:
Neo7 Bioscience – https://neo7bioscience.com
The Beljanski Foundation – https://beljanski.org

⚠️ Disclaimer: This episode is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a licensed healthcare provider.

Thanks for listening in! What did you like most about this episode? Feel free to send us a text message, and don't forget to sign up at beljanski.org/podcast

Hey there! If you've been getting value from our podcast, we’d be so grateful if you could take a moment to leave a review on Apple Podcasts or Spotify. Your support helps us reach more people, and it truly means the world. Thanks so much for taking the time—it really makes a difference!

==================

Want to stay in the loop? Sign up and grab a FREE chapter of Sylvie’s eBook! 👉 https://www.beljanski.org/podcast/

To help support cancer research, head over to https://beljanski.org and learn more.

Grab the book and support The Beljanski Foundation! Get it here: https://www.beljanski.org/book (Use code EP1 at checkout for FREE shipping)

Stay connected and follow us for the latest updates: https://linktr.ee/thebeljanskifoundation


A Miraculous Recovery

Dr. John A. Catanzaro: I've had a husband bring his wife in, carrying her in. She failed at all treatment. She was dying. There was nothing else for her to do. And this particular lady winds up living 7+ years past her diagnosis. I had so many resistant cancer cases for so many years.

Introduction to Dr. John Catanzaro

Victor Dwyer: Hey, everyone! Welcome to today's episode of The Beljanski Cancer Talk Show. We're honored to have Dr. John Catanzaro with us, a true pioneer in precision molecular medicine, who's changing the way we approach health. His groundbreaking work and personalized peptide engineering and targeted molecular interventions is helping people restore balance at the deepest cellular level by combining cutting edge science with real world healing.

Dr. John Catanzaro is leading the way toward a future where medicine is truly tailored to each individual. Get ready to discover how personalized medicine can transform your health and your life.

Sylvie Beljanski: Hello, Dr. Catanzaro. Thank you for joining us today on The Beljanski Cancer Talk show. You are a doctor, you are also a scientist, and you are also the CEO of a company called Neo7Bioscience. Is that right? 

Dr. John A. Catanzaro: That's right. That's correct, yes. 

Sylvie Beljanski: Sounds like a lot of things. You're a busy gentleman.

Can you tell us more about what you are doing and how you got there? 

The Mission of Neo7Bioscience

Dr. John A. Catanzaro: Oh, absolutely. Neo7Bioscience is a biotech company that focuses in on precision and personalized technology. So, what, basically what we do is we develop personalized therapeutics specifically surrounding peptides based upon molecular analysis.

So, we do a molecular analysis, which means that we look at the person's faulty targets, and then we develop a remediation engineering to those faulty targets. So, Neo7Bioscience started in 2019. I was in clinical practice for 25 years in integrative oncology, so I understand the space really well.

I retired back in 2017, as I mentioned, to just take a little bit of a break. And then I was called back by many friends, colleagues to continue doing what we were doing in precision medicine, right? They wanted to see it out there. So, that's why we came back and formed the company. And yeah. 

Simplifying Precision Medicine

Victor Dwyer: And can you repeat what you do again and like explaining it to a 6-year-old for me, so sorry. That way I can understand it like less lingo and more just understanding what's going on there. 

Dr. John A. Catanzaro: It's very basic from the standpoint of we just take patient samples like blood and urine, and then we analyze it to see where the bad signal targets in the disease expression are, and then we develop a personalized strategy to address those bad signals, basically. That's, in a nutshell, very simple how to explain what we do

Victor Dwyer: And that signals could be cancer or toxins, or something like that?

Dr. John A. Catanzaro: That's correct. Anything that's affecting the body in an adverse way. Those signals are known as genetic protein related signals. So, we analyze those and then we develop a fix for them 

Personalized Drug Development

Sylvie Beljanski: When people hear Texas and urine, a lot of people, at least my generation, they think of Dr. Burzynski and his antineoplaston. How different is what you are doing? 

Dr. John A. Catanzaro: Yes. What's different about what we're doing is we're doing the complete genetic expression of the individual to get a thorough picture of all the systems and communication that's going on in their body in high definition.

So, we use a very high definition technology to do it, and that allows us to be a lot more precise in our targeting because Dr. Burzynski does a great job in his work, but he's not focusing on multi-targets. Like, we're actually looking at more than one or two targets. We're looking at a multiple strategy of targets to address the underlying disorder.

And then we develop the engineering to actually address those faulty targets. So, it's a lot different. The bottom line is that the patient will have a personalized drug. In other words, their personalized drug, that will be a peptide-based. And peptides are basically an assembly of amino acids in certain constructs that allow for stabilizing the person's system.

If the system is out of regulation, then those peptides are mainly geared to help re-regulate their system and to create a better balanced signaling platform that we have observed in the analysis itself. It's a very precise way of engineering a strategy for patients, right?

So, it's not just about taking something and trying to match it to their genetics. It's manufacturing something from the beginning to the patient's specified action in their body. 

Sylvie Beljanski: But at the beginning, you start with the patient's urine? 

Dr. John A. Catanzaro: Start with their blood and urine. 

Sylvie Beljanski: Blood and urine. And then what do you do? How do you transform that into some medicine? 

Dr. John A. Catanzaro: Yes. So what happens is the blood and the urine, and, in some cases tumor tissue, right? Because the cancers do get the tumor tissue too. Those samples, the blood, urine and tumor tissue have an abundance of molecular markers.

So, what we do is we build the dataset for those molecular markers to give us a caricature of what the communication networks are looking like. So, it's about genetic data and protein data, and then our technology pipeline then does what we call a confidence ranking, mapping and simulation to the person's molecular expression and whatever disease they are diagnosed with.

In other words, whatever cancer particularly that they're affected by, we have a very vast, very big data base interface that allows us to profile their molecular expressions as to their diagnosis.

Then we get those faulty signals that the pipeline then ranks, and they're usually the most resistant targets in the person's expression. So, that means that these are ones that are really causing the problem. So, those are the ones that are selected by the technology to create the engineering for the personalized drug for it.

Sylvie Beljanski: So, you are speaking of personalized drugs. What does the end result, this personalized drug look like? 

Dr. John A. Catanzaro: What it looks like, it's a, it's a multi pool peptide. So, in other words, they're usually between 8 and 10 sequence targets that are part of that personalized drug. And there they're peptides, which means that they're, you know, they're not like your small molecule drugs or your antibodies out there. They're specifically formed by amino acid sequences that are uniquely matched to the protein pathways, right? So, the end product is a lyophilized powder that is then mixed, right? It's mixed and it will be injected intravenously or intradermally, intramuscular, intratumorally. It could be used in any of those routes of administration very effectively. 

Treatment Process and Duration

Sylvie Beljanski: And how long does the average treatment last? It's something done once, or you have to come back and stay in Texas for weeks and weeks, like chemotherapy treatment, for example. 

Dr. John A. Catanzaro: No. How it works is we have our participating physicians, so we have Neo7 participating physicians, and the physicians are responsible for managing clinically, right?

So, we're the design company. Neo7Bioscience is the design company. We add to the analysis and the design we provided to the physicians. The physicians manage their patients and the protocols for cancer are usually 12 to 16 months long. But there's flexibility in administration so a person doesn't have to be in the clinic every day. They can administer some of those, administer some of those shots at home. They can receive IVs maybe once or twice a week or what have you. And then other integrative type modalities can be combined with it.

The Neo7 design is like a hub strategy. It's like a driving strategy to help with allowing the body to respond a lot more favorably to beat the, like, the metastatic disease process. The person's got a very heavy metastases, or they got a lot of cancer in their body, it'll actually work together with these strategies to really get the person very strong in defense and regulation against the cancer activity.

Sylvie Beljanski: Is it considered, by injection, I assume it's considered as a drug, right? 

Dr. John A. Catanzaro: Yes, it's a personalized drug. The way it's working is the participating clinics have an IRB, so they work under an IRB Institutional Review Board. And that's for protection of human subjects. These IRBs are registered with the HHS, so that means that they have the leverage to use their clinical practice plus the IRB umbrella for protection of human subjects, so patients can actually do this personalized investigational treatment with safety, right? And all of our end to end, it takes about 10 weeks from the receipt of sample all the way through to the delivery of the manufactured personalized drug, right? That's not very long.

There are some patients that don't have enough time maybe, but most of the times, the patients are going through other integrative modalities to keep them strong while they're waiting. And we have very close connections with the doctors. So, in other words, we team lead with the doctors.

You know, doctors that come in our program are trained with understanding molecular medicine. They get to learn a lot about that. There’s a very solid resource for them. We have a whole team of scientists that are at our disposal all the time. So, we're geared to help many people with this type of N-of-1 strategy.

Sylvie Beljanski: When you say helping many people, what kind of cancer do you treat? Are there cancers you do not treat? Where is your best success stories? 

Dr. John A. Catanzaro: Yes. We don't turn down any cancers. So, if a person has experienced even a very rare cancer, we've actually designed for rare cancers and have had very good success.

And the reason why very pivotal is that remember, this is N-of-1 to the person rather than N-of-1 to the disease. So, when you're actually just profiling something to a disease, what you get is limited results. When you're profiling it to a person's expression and how they respond to a disease process, it's a totally different venue then, right?

The success is high because it's focusing on the person. So, even if it's a very rare resistant cancer, because you've got engineering design that's really focused on their own personalized expression of that particular response to that disease process, you're gonna more than likely hit it out of the park a high percentage at a time, and we do because of that.

Sylvie Beljanski: So solid tumor, blood cancer, anything goes. 

Dr. John A. Catanzaro: Anything goes. Yep. And the interesting thing is that, when I was in clinical practice I had so many resistant cancer cases for so many years where, you know, I've had a husband bring his wife in, carrying her in. She failed at all treatments. She was dying. There was nothing else for her to do. So she was, like a typical example of the real severe cases that would come. And this particular lady winds up living 7+ years past her diagnosis from the time that she was brought into our center.

And that was a failure case. There was no option, there was nothing that could be done for this. And we had so many patients like that through the 25 years that I was in clinical practice. And we had the opportunity to show that we can make a difference in these type of presentations because these people were just written off hospice care, blah, blah, blah.

You've heard it all probably and and then yet they wind up living 7, 10, 14 and some, or even like 16 years past their grave diagnosis. 

Sylvie Beljanski: Yeah. Yeah. We have been speaking of cancer, but what about other injuries to the body? 

Addressing Vaccine Injuries

Sylvie Beljanski: I came back just from a conference where there was a lot of talks about long COVID, for example, and the effect of the messenger RNA vaccine.

Dr. John A. Catanzaro: Yes.

Sylvie Beljanski: Has your technology apply also to that? 

Dr. John A. Catanzaro: Yes, it does. As a matter of fact, we have a collaboration with the University of North Texas in Neos7Bioscience. And what we're doing is we have a system called Spike X detect, and what that simply means is that it's not just looking for spike, it's looking at the bad signals that spike had initiated. Because we all have heard now about the turbo cancers that have come out of this and the mRNA initiated bad activity from the complications of the vaccine. And we are actually seeing this on real patient data. So, the patient data manifests that.

It's not just about detecting the spike protein. Now it becomes more important, imperative to be looking at what pathways the spike has actually dysregulated and has created a destructive path forward. So, in other words the spike is like just the very beginning, the molecular collapse that happens in initiating these turbo cancers is that these tumor suppressors are no longer suppressing anything.

The tumor promoters are promoting activity at a very fast rate, and then there's a high, a very high cellular proliferation rate that's associated with it too, because the spike protein has initiated that translation. It's transcription translation causing a massive amount of cancer cells proliferating very fast through the body.

Sylvie Beljanski: Yes. People call turbo cancer.

Dr. John A. Catanzaro: Yes, turbo cancer. 

Victor Dwyer: Yeah. One thing I wanted to ask about is what are your top three toxins that you typically see that people are coming you to? Or top three maybe toxins or top three indicators that people are coming to you with, are people coming to you and seeing, oh, they have high lead in their blood system, or something like that?

What are the top three indicators?

Dr. John A. Catanzaro: Yeah, that's a very good question.

Ad: Prostabel®

Victor Dwyer: Welcome to a new chapter in Men's Health. Prostabel® offers a natural boost for men over 50 concerned with maintaining their prostate health. The capsules are packed with 310 milligrams of Pao Pereira and 60 milligrams of Rauwolfia Vomitoria ensuring potent support for your prostate.

Experience broad spectrum support with safe and non-prescription ingredients, all backed by science. Plus, enjoy the added benefit of reduced nighttime bathroom visits, helping you achieve a more restful and uninterrupted sleep. Discover real stories and transformative experiences. Visit our website to see what others are saying about Prostabel®.

Take charge of your wellbeing with confidence and feel better naturally. Discover Maison Beljanski. Sourced from nature. Perfected by science. Enjoy a 15% discount on your first purchase with code EP2. Prostabel® – where your health journey begins.

Environmental Toxins and Cancer

Dr. John A. Catanzaro: Because, usually, something has to hit the body sideways in order for the body to respond in an adverse way, right? So like when we look at the environmental shifts that we see, we had a lot of people that had been exposed to very toxic chemicals in their jobs that they had done for years and years.

They would come in, like we've had melanomas that head to toe melanomas that were pretty much initiated by, like for instance, I'll give you an example. One of our patients was in the autobody industry and he was exposed to accelerants and drying agents and chemicals and this and that and he had that melanoma everywhere in his body, right?

We treated him over a period of a year and we cleared him completely of the melanoma.

Victor Dwyer: Wow. 

Dr. John A. Catanzaro: Yeah, we understand what's happening in those signal pathways. Some of them were actually real main cell proliferation signals, gene protein signals. Some of them were detox signals in the body that were actually gone sideways.

A lot of these different protein to protein circuitry, so complex, you get to see exactly where, and you pinpoint and then you're no longer flying blind anymore, right? You're actually seeing things a lot more clearly. And you're not just trying to throw a medication at it. You're not trying to do some kind of procedure to try to fix it. You're being more strategic to look under the hood to see what's going on. 

Victor Dwyer: Got it. 

Emotional Trauma and Cancer

Sylvie Beljanski: There are a lot of cancers which are linked to emotional trauma. How does that translate? What do you see at the level of the cells for those people?

Dr. John A. Catanzaro: Yeah, that's a really a wonderful question, too, because of the constitutional energy shifts that we see. You have some people that have a very strong, good, balanced mindset and they come in, but they have a very horrific type of cancer and, but yet emotional outlook and their body-mind connection is there.

It's just that, a lot of the times, it's just that their body's not cooperating. It's not like their mind that is creating the problem. But then we also see the other type of presentation, too, where the body-mind connection is not balanced and it's really feeding the problem.

And you can see the constitutional energy shifts there. Like, for instance, if a patient has got a systemic cancer, a lot of the times we'll see some neurogenic influences, which means that we'll see some common to neuroinflammatory presence that definitely creates a lot of neurotransmitter disturbances in the brain.

And it is related to the disease process, but it's also related to the state of the person's own mind health as well. And we get to see that, too. And in those cases, if we see that there's a heavy burden on neurogenic related inflammatory response, then we can always help to get that to regulate by creating the engineering, including it in the engineering of the personalized drug that we develop.

So, generally what people notice is that they get a very strong positive shift in their state of constitutional energy when they start the peptides. It's almost like the alignment to their bodies is just, it's almost like a perfect alignment for them. They notice immediately that they're putting something, life getting in their body, rather than something that's hitting them in a harmful way.

Sylvie Beljanski: The process is pretty heavy. It's a personalized, the development of a drugs and it's, it's in injections. It's not something simple and to be taken lightly. 

The Future of Personalized Medicine

Sylvie Beljanski: However, it seems that, from a protection, prevention point of view, that would be perfect because you would be able to see probably the signals long before the development of the symptoms.

Dr. John A. Catanzaro: Yes, very true. That's exactly what we get to see. And we've had opportunity to look at many patient datasets. Like we get to, we get the expression of these different disease patterns and we get to see commonalities. We get to see individual things that are uniquely different. And when you talk about an N-of-1 strategy, what you're really talking about, no two people are alike, and you can't use patient A on patient B.

You can't, it's not a ‘one size fits all.’ So it's, particularly to the person, even though you might see common expressions. So, the interesting part of that is, is that we could have two people that have this identical same cancer, but when we look at their personalized design, it may have only one or two targets that are similar, but their sequences for the engineering are completely different because the driving force of that is how their body either is, is responding from the immune standpoint, like their immune system has got its own code, they have their own code in the, in their immune systems that can help to fight their pro, their disease process in a very intelligent fashion. And when you toggle those switches to their own immune code, it's very powerful. 

Victor Dwyer: Yeah, it seems like chemotherapy is like a kind of a nuke that kind of hits everything and hurts everything, where you guys are like the sniper that, like, very targeted in a way. 

Dr. John A. Catanzaro: Yeah, that's right. That’s a very good analogy there.

I like it because that's exactly, it’s like a precision strike, right? 

Sylvie Beljanski: Yeah. But it's also like a little bit a biohack thing where you enter the system and you rebalance it in a way. 

Dr. John A. Catanzaro: Yes. Yes, exactly. Yes. So, there's that resilience component to it, right? So, it's not just about hitting the precise target, it's also actually facilitating a resilience response, too.

That's the reason why at Neo7Bioscience, we do active disease, we do resilience, and we do the Spike X Detect, which is part of that vaccine related injury and complications. So, all those are our three focal areas. Active disease. We do cancer, we do autoimmune, neurodegenerative, some rare diseases and also chronic infections, mysterious illnesses. We've actually done all of that. 

Sylvie Beljanski: So, to, to make it simple for the people who are listening. 

How to Get Started with Neo7Bioscience

Sylvie Beljanski: If I have a vaccine injury, what should I do? 

Dr. John A. Catanzaro: Yeah, simply if you wanted to use Neo7 to actually detect what's going on you're just gonna submit a blood test. If, first of all, we have to have you, we have to assign you to a doctor.

So, if you have your doctor and your doctor wants to participate, he could sign up on Neo7bioscience. And then it's as simple as getting the blood and sending the blood to our contracted labs to do all the work, getting all the data built. And then getting the final, the final report and design to help with the going forward strategy for the personalized design and drug.

Sylvie Beljanski: If my doctor is not affiliated with you, how do I get name network of doctors who are working with your approach? 

Dr. John A. Catanzaro: Yeah, we have doctors that actually do things like, they're actually part of our program that also do telemedicine, so they can do a lot of things remotely. You don't have to necessarily be in the office to do all of this. Some doctors are actually equipped to do that. And we will find you a doctor to work with.

Sylvie Beljanski: You have a website with a map of doctors or a list of doctors? 

Dr. John A. Catanzaro: Yes. Yes, we do. Yep, we do. It's neo7bioscience.com. 

Sylvie Beljanski: Can you repeat that?

Dr. John A. Catanzaro: neo7bioscience, all one word, dot com. And it's the number seven. 

Seven is the perfect number. So, the reason why Neo7, is seven is the perfect number. Seven is seven continents. Seven is always about renewal, and something new, right? So we, the Neo7 part was all about the new part of developments. And we actually position ourselves in that way from the standpoint of innovation.

We like to stay ahead of the curve that way. So, you could go on the website., neo7bioscience.com. It’s also a place where you can go, it says Inquiries. You can enter your information under the Inquiries, under Contact Us, and then enter in if you're a physician or if you're a patient. And then that comes into our team and the team actually then will contact the person that's inquiring. 

Dr. Catanzaro's Background and Vision

Sylvie Beljanski: And before being involved with Neo7Bioscience, you were practicing medicine. What kind of doctor were you? 

Dr. John A. Catanzaro: I was, I worked in integrative oncology, so I graduated from Bastyr University.

And my focus was integrative oncology. And practiced for 25 years, had a very large center outside of Seattle. We were a training center for Bastyr as well, for doctors and residents. And we had eight physicians in our center. We also had a lab, so we were doing research, so we had a lab as well.

And then, and then I decided to retire and just take a break before I came back and formed Neo7Bioscience 

Sylvie Beljanski: In large facilities like the one you were working at at Seattle, there are some mandatory protocols that people, it's ‘one medicine fits all.’

Dr. John A. Catanzaro: Yeah.

Sylvie Beljanski: But, what, as a doctor, your experience and your frustration, and is that what led you to create something involved in precision medicine?

Dr. John A. Catanzaro: Yes, it did actually because when we were working with a large number of patients with all these resistant cancers, we are often, if we were communicating with the conventional institutions, it was always frustrating. So, patients would come in and they would get centralized care with us because we took the time to focus in on them as individuals.

So, we had a very strong pride in the fact that we would get people better because we spent time with them because we not just understood their illness, but we understood the whole body connection. And then we were also focusing in on more technology advancements at the same time.

In the community, in the conventional community, it's very difficult because it's a ‘one size fits all’ thinking and it's not easy to communicate that individualized movement with the regular institutionalized movement. It's a very challenging thing. And a lot of the times you're fought in some cases to provide for the patient.

So, in other words they become more adversarial than they become helpful. 

Sylvie Beljanski: Yeah.

Dr. John A. Catanzaro: You know what I mean? And, but the thing is that was all that cumulative, that whole cumulative experience is what led me to move into this more of the biotechnology development because I just figured we would be able to work with doctors, team with them, and provide a technology that can help a thousand x more patients than I would be able to help in a clinical practice setting by ourselves, by myself. 

Sylvie Beljanski: So in, in a few words, why do you think that for a patient who is diagnosed with cancer, the experience or, and/or the outcome will be better if using these technologies and rather than going to, to Seattle to a big hospital.

Dr. John A. Catanzaro: Because of the fact that, again, it's focusing in on this N-of-1, which means N-of-1 person strategy which is getting more direct focus on what it is going to take to get that person to become disease free. So, we are really goal oriented to get these patients in no evidence of disease expression.

And we have a good amount of success in getting them there by coordinating with our doctors who are very much involved in personalized and precision medicine because they're focused in personalized precision medicine which goes outside of, against the institutional model, basically. And they have the highest success rate because these patients are having the individualized attention that they need.

When you put the technology in that space, it powers it up so much. When you have a good core technology and molecular technology, like we do in personalized engineering, you're actually building something that is unique to that patient. It's unique to them, to their expression.

And there's really nothing out there right now like that. You have some organizations like CeGAT in Germany that does something similar, but not in the same definition that we do it. They take a long time to do it. They have some missing elements in their technology.

We have been able to figure out, through our experience, what that high definition precision looks like. When you go through our program and, like for instance, if you went through the program and you had a final review and you met with me, and I go through that descriptions with you on the final report and how it all relates to the process, patients and doctors are amazed about how vast, this could be. How effective it could be to a vast amount of people, basically. 

Sylvie Beljanski: Since it is a drug, is it covered by insurance? 

Dr. John A. Catanzaro: No, it's, it is not covered by insurance because it's an investigational personalized drug. Patients pay out of their pocket.

And I gave a little bit of a preview of the end to end, takes about 10 weeks to, from sample submission to the delivery of the, the peptides to the pharmacy. So, how it works is that the manufacturer dispenses it to the pharmacy, and the pharmacy dispenses it back to the physician to give to the patient. So, that's how it works.

So, what the physician does is the physician writes a prescription, right? So, the prescription is the personalized design that goes to the pharmacy, then to the manufacturer. The manufacturer then releases the product, goes back to the pharmacy, and then the pharmacy dispenses it to the patient. That's how it works. And the price tag for it is between 50 and $60,000 for a year worth of therapy, and the patient is gonna be receiving 125 vials of the personalized drug. 120 vials, I'm sorry, 120 vials. 

Sylvie Beljanski: To be taken through injection, right? 

Dr. John A. Catanzaro: Yes. To be taken as injection, either IVIM, intratumorally, intradermally. And the personalized drug, because it's a lyophilized peptide, pooled peptide complex, is stored in a traditional freezer. It's a 20 standard freezers, like 20 degrees Celsius. It could last, it'd be stored in a standard freezer for up to three years. If you stored it in long-term storage at 80, minus 80, then it's usually indefinite, right? But, the minus 20, it can last up to three years in a traditional freezer, right?

And once it's mixed the patient has to use it within 30 days, right? 'Cause it has a 30 day shelf life 

Sylvie Beljanski: And this treatment is to be taken together with another regimen of supplements or do you provide lifestyle recommendations, or is it just a drug, and that's it? 

Dr. John A. Catanzaro: In the final report that we review, we actually match available repurposed drugs that are specific for the cancer as well as natural agents.

So, we list those as well, natural agents that would actually facilitate and work well together with the personalized peptides. And then we also encourage other things, people who are doing HBOT or they're doing laser type therapies, or they're doing biohomeopathic therapies, there's a lot of integrative therapies and the personalized peptides match very well with these therapies.

Not only that, but even in the conventional world where people are receiving chemotherapy, radiation, or proton radiation, or any of those things, or biologics or conventional immunotherapy, the personalized program sensitizes the system to accept them better, and it helps to facilitate protection and regeneration.

So, in other words, when you do the hub strategy, it actually facilitates a better, a better action overall, even so, regarding using conventional or integrative. It doesn't matter if you use both, together, they combine very well. And we have patients that are on chemotherapy, very toxic regimens. And we position the personalized therapeutic in their regimens. 

Sylvie Beljanski: Accordingly, yeah. You mentioned herbs. How do you test to see which herb is going to work together with your approach? 

Dr. John A. Catanzaro: The way our platform is designed, a pipeline will give a general, a like of the natural agents.

It's going to give a general list of these natural botanicals and nutrients that are more compatible for the person based upon their expression, molecular expression, and based upon its effects in the disease itself. So, it's matched-based on those terms. And then we also have, in the report, we list the clinical trials that are going on.

So, that the patient has exposure to ongoing clinical trials, so they know it's what's up to date. So, that's also included in the report. It's a very robust report. It's about 37 pages long, so it's pretty robust. 

Sylvie Beljanski: I know that you are coming to Austin, Texas. I’m going to give a presentation about a mix of herbs that are showing no, it is a mice study, but compared to the control group, the mice that have taken those herbs have absolutely zero metastasis.

Dr. John A. Catanzaro: Uhhuh

Sylvie Beljanski: Is it something that you think could work together with your system? 

Dr. John A. Catanzaro: Oh, absolutely. Yes. Yes. I do believe that it would work. It would work well. 

Sylvie Beljanski: I would love, I would love to see if there would be some synergy here.

Dr. John A. Catanzaro: Yeah. Uhhuh. We have a very robust technology platform, so there's a lot of capabilities. And the nice thing about this co-founder, he's a molecular biophysicist. He's a Johns Hopkins alumnus. He's an Elsevier executive. He and I are friends, colleagues. We developed the company together.

Our team are very strong in molecular surveillance and drug discovery personalized drug discovery, and they're bioinformaticist and data specialists. So, we have a very brilliant team and they're not just from the United States, they're also from Russia. They're from Brazil, they're from India, they're from China. We have a very robust team. 

Sylvie Beljanski: Excellent. 

Conclusion and Contact Information

Sylvie Beljanski: Victor, you have some additional question? 

Victor Dwyer: No, I think that's it. Yeah, thank you so much. Please tell the audience how to find more about you and everything else. That'd be great. 

Dr. John A. Catanzaro: Yes. Oh, thank you. You could find more about the company on the neo7bioscience.com, as I mentioned. I'm also on BeyondBio and I, my, I can provide the link for you. It's, the X link is Beyond Bio, which I'm on there. I'm also on Substack which I actually contribute regularly on Substack, as well as on LinkedIn where I have my Linked, LinkedIn profile, so I could provide all those links for you, and then you can always get ahold of me.

The best way to get ahold of me is through the company because I don't take direct submissions because I got so much going on. 

Sylvie Beljanski: Of course.

Dr. John A. Catanzaro: Yeah, 

Victor Dwyer: Awesome. Thank you so much for joining! And, audience, thank you so much for people that have listened this far. This is The Beljanski Cancer Talk Show, and we'll catch you next time.

Sylvie Beljanski: Thank you.

Victor Dwyer: Thanks.



People on this episode

Head Shot

Sylvie Beljanski

Host
Head Shot

Victor Dwyer

Host